US Patent

US11116717 — Soluble estradiol capsule for vaginal insertion

Formulation · Assigned to TherapeuticsMD Inc · Expires 2032-11-21 · 7y remaining

Vulnerability score 25/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects a soluble estradiol capsule designed for vaginal insertion to treat vulvovaginal atrophy.

USPTO Abstract

According to various embodiments of this disclosure, pharmaceutical formulations comprising solubilized estradiol are provided. In various embodiments, such formulations are encapsulated in soft capsules which may be vaginally inserted for the treatment of vulvovaginal atrophy.

Drugs covered by this patent

Patent Metadata

Patent number
US11116717
Jurisdiction
US
Classification
Formulation
Expires
2032-11-21
Drug substance claim
No
Drug product claim
Yes
Assignee
TherapeuticsMD Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.